PMID- 36105161
OWN - NLM
STAT- PubMed-not-MEDLINE
LR  - 20220917
IS  - 2214-0883 (Electronic)
IS  - 2095-1779 (Print)
IS  - 2214-0883 (Linking)
VI  - 12
IP  - 4
DP  - 2022 Aug
TI  - In situ synthesis of a spherical covalent organic framework as a stationary phase 
      for capillary electrochromatography.
PG  - 610-616
LID - 10.1016/j.jpha.2022.06.005 [doi]
AB  - Covalent organic frameworks (COFs) are a novel type of crystalline porous organic 
      polymer materials recently developed. It has several advantages in 
      chromatographic separation field, such as high thermal stability, porosity, 
      structural regularity, and large specific surface area. Here, a novel spherical 
      COF 1,3,5-tris(4-aminophenyl)benzene (TAPB) and 
      2,5-bis(2-propyn-1-yloxy)-1,4-benzenedicarboxaldehyde (BPTA) was developed as an 
      electrochromatographic stationary phase for capillary electrochromatography 
      separation. The COF TAPB-BPTA modified capillary column was fabricated via a 
      facile in situ growth method at room temperature. The characterization results of 
      scanning electron microscopy (SEM), Fourier transform infrared 
      (FT-IR) spectroscopy, and X-ray diffraction (XRD) confirmed that COF TAPB-BPTA 
      were successfully modified onto the capillary inner surface. The 
      electrochromatography separation performance of the COF TAPB-BPTA modified 
      capillary was investigated. The prepared column demonstrated outstanding 
      separation performance toward alkylbenzenes, phenols, and chlorobenzenes 
      compounds. Furthermore, the baseline separations of non-steroidal 
      anti-inflammatory drugs (NSAIDs) and parabens with good efficiency and high 
      resolution were achieved. Also, the prepared column possessed satisfactory 
      precision of the intra-day runs (n = 5), inter-day runs (n = 3), and parallel 
      columns (n = 3), and the relative standard deviations (RSDs) of the retention 
      times of tested alkylbenzenes were all less than 2.58%. Thus, this new COF-based 
      stationary phase shows tremendous application potential in chromatographic 
      separation field.
CI  - (c) 2022 The Author(s).
FAU - He, Ning
AU  - He N
AD  - Department of Orthopedics Trauma and Microsurgery, Zhongnan Hospital of Wuhan 
      University, School of Pharmaceutical Sciences, Wuhan University, Wuhan, 430072, 
      China.
AD  - Key Laboratory of Combinatorial Biosynthesis and Drug Discovery, Ministry of 
      Education, Hubei Province Engineering and Technology Research Center for 
      Fluorinated Pharmaceuticals, Wuhan, 430071, China.
FAU - Li, Zhentao
AU  - Li Z
AD  - Department of Orthopedics Trauma and Microsurgery, Zhongnan Hospital of Wuhan 
      University, School of Pharmaceutical Sciences, Wuhan University, Wuhan, 430072, 
      China.
AD  - Key Laboratory of Combinatorial Biosynthesis and Drug Discovery, Ministry of 
      Education, Hubei Province Engineering and Technology Research Center for 
      Fluorinated Pharmaceuticals, Wuhan, 430071, China.
FAU - Hu, Changjun
AU  - Hu C
AD  - Department of Orthopedics Trauma and Microsurgery, Zhongnan Hospital of Wuhan 
      University, School of Pharmaceutical Sciences, Wuhan University, Wuhan, 430072, 
      China.
FAU - Chen, Zilin
AU  - Chen Z
AD  - Department of Orthopedics Trauma and Microsurgery, Zhongnan Hospital of Wuhan 
      University, School of Pharmaceutical Sciences, Wuhan University, Wuhan, 430072, 
      China.
AD  - Key Laboratory of Combinatorial Biosynthesis and Drug Discovery, Ministry of 
      Education, Hubei Province Engineering and Technology Research Center for 
      Fluorinated Pharmaceuticals, Wuhan, 430071, China.
LA  - eng
PT  - Journal Article
DEP - 20220620
PL  - China
TA  - J Pharm Anal
JT  - Journal of pharmaceutical analysis
JID - 101579451
PMC - PMC9463497
OTO - NOTNLM
OT  - Capillary electrochromatography
OT  - Covalent organic frameworks
OT  - Electrochromatographic separation
OT  - In situ growth method
COIS- The authors declare that there are no conflicts of interest.
EDAT- 2022/09/16 06:00
MHDA- 2022/09/16 06:01
PMCR- 2022/06/20
CRDT- 2022/09/15 02:16
PHST- 2022/03/25 00:00 [received]
PHST- 2022/06/12 00:00 [revised]
PHST- 2022/06/15 00:00 [accepted]
PHST- 2022/09/15 02:16 [entrez]
PHST- 2022/09/16 06:00 [pubmed]
PHST- 2022/09/16 06:01 [medline]
PHST- 2022/06/20 00:00 [pmc-release]
AID - S2095-1779(22)00057-0 [pii]
AID - 10.1016/j.jpha.2022.06.005 [doi]
PST - ppublish
SO  - J Pharm Anal. 2022 Aug;12(4):610-616. doi: 10.1016/j.jpha.2022.06.005. Epub 2022 
      Jun 20.